ImpactLife shares highlights from World Sickle Cell Disease Awareness Day event
Community members and blood center employees gathered on Thursday, June 19, to learn about the importance of blood transfusions in providing supportive care for sickle cell patients and to hear personal experiences from those who live with sickle cell disease, or who have lost loved ones to the genetically inherited blood disorder. Speakers included Beleta Rush, who shared writings and experiences from the lives of her two daughters, Lynn and Bobbie.
View and download video clips from the event, below, or on the ImpactLife web site.
Dr. Meredith Parsons, Clinical Assistant Professor of Pathology from University of Iowa, provided an overview on sickle cell disease, how it affects patients, and the importance of having appropriately matched units of blood available for patients who are likely to receive multiple rounds of blood transfusions throughout their lives.
Shyneeta Rush, Supervisor, Donor Services, described the blood center's Red4Life program and efforts by the blood center to identify donors who are an appropriate match for sickle cell disease patients.
Cheryl Easley, of the ImpactLife donor scheduling team, helped organize the event, and recognized sickle cell 'Warriors In Battle' as well as 'Winged Warriors,' who have passed after living with the disease throughout their lives.
Lamour Bluitt has two sisters living with sickle cell disease, and has authored a book on their experiences, A Child Born with Sickle Cell: the Untold Secret.
About Sickle Cell Disease
Sickle dell disease is an inherited blood disorder that affects red blood cells. It is the most common hereditary disorder and currently affects more than 100,000 Americans, predominantly people of African descent. The red blood cells in patients with sickle cell disease can become 'sickled' in shape, which can cause the cells to become stuck in small blood vessels. Patients can experience pain and anemia and are at increased risk for strokes and other types of organ damage. When patients experience a sickle cell crisis, red cell transfusion is a major form of therapy to relieve symptoms.
Patients with sickle cell disease frequently receive transfusions of red blood cells to help treat symptoms of a sickle cell crisis. But finding appropriately matched units for sickle cell disease patients is a challenge for blood providers. With more frequent blood transfusions, patients with sickle cell disease can develop antibodies that are directed against red blood cell antigens.
This process, called alloimmunization, makes it important for patients to receive antigen-negative blood types that are more generally found in donors of African descent. To help increase the diversity of the blood center's donor base, ImpactLife has created a donor program called Red4Life. Under Red4Life, the blood center identifies and recruits donors who may be an appropriate antigen match for patients with sickle cell disease. These donors are then invited to join the Red4Life program and receive special donor rewards and additional points to use in the ImpactLife Donor Loyalty Store. (Learn more at www.bloodcenter.org/red4life.)
About ImpactLife
ImpactLife's mission is to save lives by engaging donors, supporting partners, and advancing medicine. Founded in 1974, ImpactLife supplies blood products and services to hundreds of hospitals, emergency services organizations, clinical researchers, and other blood centers throughout Iowa, Illinois, Wisconsin, and Missouri. The nonprofit blood provider is ranked among the leading 12 blood suppliers in the United States. For more information on current blood inventory levels, our donor promotions, and more, see www.bloodcenter.org and find us @impactlifeblood on Facebook, X, Instagram, Threads, YouTube, and LinkedIn.
Attachments Beleta Rush
ImpactLife – World Sickle Cell Disease Awareness Day group photo
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Intensified Competition is Likely to Drive Product Innovation and Refine Patient Management Strategies
India's diabetes market is projected to grow at 7.3% annually, reaching US$3.52 billion by 2025. Key trends include increased adoption of continuous glucose monitoring (CGM), digital health solutions, and advanced therapeutic devices. Regulatory updates and strategic partnerships are fostering growth. Indian Diabetes Devices and Therapeutics Market Dublin, July 08, 2025 (GLOBE NEWSWIRE) -- The "India Diabetes Devices and Therapeutics Market Investment Opportunities - Q2 2025 Update" report has been added to diabetes market in India is expected to grow by 7.3% on annual basis to reach US$3.52 billion in 2025. The diabetes market in the country has experienced robust growth during 2020-2024, achieving a CAGR of 7.7%. This upward trajectory is expected to continue, with the market forecast to grow at a CAGR of 6.1% during 2025-2029. By the end of 2029, the diabetes market is projected to expand from its 2024 value of USD 3.28 billion to approximately USD 4.77 billion. This report provides a detailed data-centric analysis of the diabetes industry in India, covering market opportunities and analysis across a range of diagnosis and monitoring devices, therapeutics, domains. With over 50+ KPIs at the country level, this report provides a comprehensive understanding of diabetes market dynamics, market size and forecast, and market share statistics. The Indian diabetes devices and therapeutics market is being reshaped by increased CGM adoption, enhanced digital health integration, advancements in therapeutic delivery systems, and evolving regulatory frameworks. These trends are expected to intensify over the next 2-4 years, leading to improved patient monitoring, more precise treatment adjustments, and overall market expansion. The Indian market features a blend of multinational corporations and domestic innovators in diabetes care. A multi-tiered healthcare system with diverse reimbursement pathways provides opportunities for established and emerging players. A dynamic mix of multinational leaders and emerging domestic players mark the Indian diabetes devices and therapeutics market. Recent strategic partnerships, mergers, and acquisitions are reshaping competitive dynamics, with a growing emphasis on digital integration and regulatory alignment. In the coming years, intensified competition and strategic consolidation are expected to drive innovation and enhance patient management across India. The competitive landscape is expected to evolve with further consolidation as multinational firms expand their digital health capabilities and local entrants secure strategic alliances. Industry reports suggest emerging segmentation between providers of conventional devices and those focusing on digital innovations. Intensified competition is likely to drive product innovation and refine patient management strategies. Over the next 2-4 years, strategic collaborations and market consolidation are expected to reinforce India's competitive positioning. Expand Adoption of Continuous Glucose Monitoring (CGM) Indian healthcare providers are incorporating continuous glucose monitoring systems into diabetes management programs across urban centers such as Delhi, Mumbai, and Bangalore. Pilot initiatives in multi-specialty hospitals are using CGM data to tailor treatment regimens. Recent revisions in reimbursement policies by state health schemes and updated clinical guidelines have supported broader CGM use. Local clinical studies emphasize the value of real-time glucose data to enhance glycemic control, aligning with global MedTech advancements. CGM adoption is expected to intensify as policy frameworks and clinical evidence mature. Enhanced monitoring will facilitate timely treatment modifications and better patient outcomes across India. Integrate Digital Health Solutions for Remote Monitoring Digital platforms for remote monitoring and telemedicine are being implemented in diabetes care settings in India. Regional health systems are piloting centralized dashboards to consolidate patient data and support remote consultations. Government initiatives to expand digital health infrastructure and increase investments in healthcare IT are key enablers. Broader shifts in healthcare delivery models, including insurer support for telemedicine, have accelerated this integration. Digital health solutions are anticipated to grow steadily, improving connectivity between patients and providers. Over the medium term, the trend is expected to intensify, resulting in more efficient clinical decision-making and diabetes management. Advance Therapeutic Delivery Systems Connected therapeutic devices, such as smart insulin pens and automated insulin pumps, are entering the Indian market. Clinical trials in leading hospitals evaluate these systems for their potential to improve dosing accuracy and adherence. Technological innovation and encouraging findings from local clinical evaluations support the development of these devices. Increased research and development investments and adjustments in reimbursement approaches further drive market entry. The adoption of connected therapeutic devices is expected to grow as clinical protocols and reimbursement models evolve. This trend may lead to more precise treatment regimens and overall improvements in diabetes management across India. Regulatory and Reimbursement Frameworks Indian regulatory authorities are updating approval processes and reimbursement models to better accommodate new diabetes devices and therapies. Recent guidelines from health agencies reflect efforts to streamline market access for innovative solutions. Broader healthcare reform initiatives and cost-containment strategies are prompting these regulatory adjustments. Recent publications highlight the need for clear reimbursement pathways to support conventional and digital diabetes care. A more defined regulatory framework is anticipated to boost market confidence and attract further investments in advanced diabetes technologies. These changes will likely intensify over the next few years, paving the way for broader market growth and improved patient access. Key Players and New Entrants Multinational manufacturers maintain a strong market presence through longstanding collaborations with major hospitals and clinics. These companies offer comprehensive portfolios that include both monitoring devices and therapeutic systems. Local startups and technology firms are entering the market with digital health solutions and connected therapeutic devices tailored to Indian needs. Recent market analyses indicate that these new entrants leverage regional pilot programs and strategic collaborations to gain traction. Review Recent Partnerships, Mergers, and Acquisitions Recent publications report partnerships between established firms and domestic innovators to enhance data connectivity and device interoperability. Mergers and acquisitions over the past 12 months suggest efforts to consolidate expertise and expand product offerings in the Indian market. These strategic activities contribute to a more integrated market landscape, fostering shared innovation and streamlined regulatory compliance. Consolidation trends align product development with the evolving needs of India's healthcare system. Diabetes Devices and Therapeutics Market Share by Category Diagnosis and Monitoring Devices Therapeutics Diabetes Devices and Therapeutics Market Share by Diagnosis and Monitoring Devices Blood Glucose Monitoring Devices Insulin Delivery Devices Diabetes Management and Mobile Applications Artificial Pancreas Devices Diabetes Devices and Therapeutics Market Share by Blood Glucose Monitoring Devices Self-Monitoring Blood Glucose Devices Continuous Blood Glucose Monitoring Devices Test Strips Lancets Diabetes Devices and Therapeutics Market Share by Insulin Delivery Devices Insulin Pumps Insulin Pens Insulin Syringes Diabetes Devices and Therapeutics Market Share by Therapeutics Oral Anti-Diabetic Drugs Insulin Non-Insulin Injectable Drugs Combination Drugs Diabetes Devices and Therapeutics Market Share by Oral Anti-Diabetic Drugs Alpha-Glucosidase Inhibitors DPP-4 Inhibitors SGLT-2 Inhibitors Diabetes Devices and Therapeutics Market Share by Insulin Basal or Long-Acting Bolus or Fast-Acting Traditional Human Insulin Drugs Insulin Biosimilars Diabetes Devices and Therapeutics Market Share by Non-Insulin Injectable Drugs GLP-1 Receptor Agonists Amylin Analogue Diabetes Devices and Therapeutics Market Share by Combination Drugs Combination Insulin Oral Combination Diabetes Devices and Therapeutics Market Share by Route of Administration Subcutaneous Intravenous Others Diabetes Devices and Therapeutics Market Share by Type of Diabetes Type 1 Diabetes Type 2 Diabetes Diabetes Devices and Therapeutics Market Share by Distribution Channels Online Pharmacies Hospital Pharmacies Retail Pharmacies Diabetes Devices and Therapeutics Market Share by End User Hospitals Diabetes Clinics Homecare Key Attributes: Report Attribute Details No. of Pages 50 Forecast Period 2025 - 2029 Estimated Market Value (USD) in 2025 $3.76 Billion Forecasted Market Value (USD) by 2029 $4.77 Billion Compound Annual Growth Rate 6.1% Regions Covered India For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Indian Diabetes Devices and Therapeutics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Yahoo
3 hours ago
- Yahoo
Strategic Collaborations and Local Innovations Reshape the $24.58 Billion Market
The Asia Pacific diabetes market is set for growth, expected to expand annually by 8.8% to reach $24.58 billion by 2025. Significant trends include increased diabetes prevalence and digital health adoption, driving demand for monitoring and therapeutic solutions. Enhanced policy reforms and insurance coverage are fostering market access, while rising competition is reshaping the landscape with strategic alliances and localized innovation. The comprehensive report analyzes diagnosis and monitoring devices and therapeutics, exploring market dynamics and opportunities. Get insights on the competitive environment, segment growth, and investment potential within the diabetes market in Asia Pacific. Asia-Pacific Diabetes Devices and Therapeutics Market Dublin, July 08, 2025 (GLOBE NEWSWIRE) -- The "Asia-Pacific Diabetes Devices and Therapeutics Market Investment Opportunities - Q2 2025 Update" report has been added to diabetes market in Asia Pacific is expected to grow by 8.8% on annual basis to reach US$24.58 billion in 2025. The diabetes market in the region has experienced robust growth during 2020-2024, achieving a CAGR of 9.4%. This upward trajectory is expected to continue, with the market forecast to grow at a CAGR of 7.4% during 2025-2029. By the end of 2029, the diabetes market is projected to expand from its 2024 value of USD 22.59 billion to approximately USD 35.43 billion. This report provides a detailed data-centric analysis of the diabetes industry in Asia Pacific, covering market opportunities and analysis across a range of diagnosis and monitoring devices, therapeutics, domains. With over 50+ KPIs at the country level, this report provides a comprehensive understanding of diabetes market dynamics, market size and forecast, and market share statistics. The market features participation from both established multinational corporations and emerging regional manufacturers. The competitive environment is characterized by varied regulatory frameworks and economic conditions across the Asia Pacific. Publications from the past 12 months indicate a segmented market with regional differentiation in product offerings and market strategies. The market is evolving with a mix of longstanding multinational entities and agile local innovators. With an expected trend toward consolidation and strategic collaborations, the next 2-4 years will likely see a reshaping of competitive dynamics focused on localized product innovation and regulatory alignment. The diabetes devices and therapeutics market in Asia Pacific is being reshaped by increased diabetes prevalence, the adoption of digital health solutions, and evolving policy frameworks. These drivers are expected to intensify over the next 2-4 years, leading to more targeted and data-supported approaches in managing diabetes across diverse regional Rising Diabetes Prevalence and Healthcare Demand Recent publications (2023-2024) report a measurable increase in diabetes cases across Asia Pacific, with significant examples in China, India, and several Southeast Asian nations. Rising incidences of type 2 diabetes are increasing the need for effective monitoring and therapeutic interventions. Demographic shifts (aging populations, urbanization) and evolving lifestyle patterns drive the demand. Adjustments in healthcare financing and insurance reforms across the region support wider access to diagnostic devices and therapies. Anticipate a steady intensification in demand for devices that integrate daily management tools. Healthcare systems will likely expand investments in diabetes-related technologies to address the growing burden. Leverage Digital Integration and Remote Monitoring Solutions Recent regional studies highlight the increased adoption of continuous glucose monitoring (CGM) systems and telehealth services, especially in Japan and South Korea. Various Asia Pacific markets have initiated pilot programs integrating remote monitoring with traditional care models. Technological progress and supportive regulatory policies in digital health are key drivers. Increased investments in digital infrastructure by governments and insurers foster the adoption of connected devices. Expect further penetration of digital health solutions, with remote monitoring playing a more central role in clinical decision-making. Enhanced data analytics are likely to support more personalized diabetes management strategies regionally. Activate Policy Reforms and Insurance Coverage Enhancements Recent reforms in countries like Singapore and Australia have expanded reimbursement for diabetes management devices. Publications from late 2023 detail shifts in regulatory frameworks that now favor broader insurance coverage for innovative therapeutics. Government initiatives focused on reducing long-term healthcare expenditures and improving chronic disease management drive policy changes. Broader insurance reforms align with healthcare objectives to support preventive care and early intervention. The convergence of supportive policies and insurance incentives will further facilitate market access for new devices and therapies. Ongoing regulatory clarifications will likely encourage domestic and international investments in the region. Map Key Players and New Entrants Major global companies continue investing in research and development to maintain their regional presence. Local manufacturers, particularly in India and China, are entering the market with products tailored to regional cost structures and clinical needs. New entrants are leveraging localized expertise to address gaps in the current market, supported by regional demand for cost-effective solutions. Evaluate Strategic Collaborations and Market Consolidation Recent transactions in the last 12 months have seen collaborations between device manufacturers and healthcare providers in Southeast Asia and Australia. Strategic alliances emerge as companies seek to expand their product portfolios and market reach through mergers and acquisitions. The competitive landscape will likely experience increased consolidation as larger players acquire or partner with regional innovators. Firms that successfully navigate regulatory requirements and invest in localized development are positioned to gain competitive advantages. Forecast Competitive Shifts Continued regulatory reforms and heightened demand for diabetes management solutions will attract further competition. Specialized product developments addressing country-specific needs may lead to a more segmented competitive environment. Investment in research, strategic partnerships, and adaptation to local regulatory environments will be critical for sustaining market leadership. A bundled offering, combining the following 12 reports, covering 480 tables and 648 figures: Asia Pacific Diabetes Devices and Therapeutics Market Opportunity and Future Growth Dynamics (Databook) Australia Diabetes Devices and Therapeutics Market Opportunity and Future Growth Dynamics (Databook) China Diabetes Devices and Therapeutics Market Opportunity and Future Growth Dynamics (Databook) India Diabetes Devices and Therapeutics Market Opportunity and Future Growth Dynamics (Databook) Indonesia Diabetes Devices and Therapeutics Market Opportunity and Future Growth Dynamics (Databook) Japan Diabetes Devices and Therapeutics Market Opportunity and Future Growth Dynamics (Databook) Malaysia Diabetes Devices and Therapeutics Market Opportunity and Future Growth Dynamics (Databook) Philippines Diabetes Devices and Therapeutics Market Opportunity and Future Growth Dynamics (Databook) Singapore Diabetes Devices and Therapeutics Market Opportunity and Future Growth Dynamics (Databook) South Korea Diabetes Devices and Therapeutics Market Opportunity and Future Growth Dynamics (Databook) Taiwan Diabetes Devices and Therapeutics Market Opportunity and Future Growth Dynamics (Databook) Thailand Diabetes Devices and Therapeutics Market Opportunity and Future Growth Dynamics (Databook) Scope for Each Report Diabetes Devices and Therapeutics Market Share by Category Diagnosis and Monitoring Devices Therapeutics Diabetes Devices and Therapeutics Market Share by Diagnosis and Monitoring Devices Blood Glucose Monitoring Devices Insulin Delivery Devices Diabetes Management and Mobile Applications Artificial Pancreas Devices Diabetes Devices and Therapeutics Market Share by Blood Glucose Monitoring Devices Self-Monitoring Blood Glucose Devices Continuous Blood Glucose Monitoring Devices Test Strips Lancets Diabetes Devices and Therapeutics Market Share by Insulin Delivery Devices Insulin Pumps Insulin Pens Insulin Syringes Diabetes Devices and Therapeutics Market Share by Therapeutics Oral Anti-Diabetic Drugs Insulin Non-Insulin Injectable Drugs Combination Drugs Diabetes Devices and Therapeutics Market Share by Oral Anti-Diabetic Drugs Alpha-Glucosidase Inhibitors DPP-4 Inhibitors SGLT-2 Inhibitors Diabetes Devices and Therapeutics Market Share by Insulin Basal or Long-Acting Bolus or Fast-Acting Traditional Human Insulin Drugs Insulin Biosimilars Diabetes Devices and Therapeutics Market Share by Non-Insulin Injectable Drugs GLP-1 Receptor Agonists Amylin Analogue Diabetes Devices and Therapeutics Market Share by Combination Drugs Combination Insulin Oral Combination Diabetes Devices and Therapeutics Market Share by Route of Administration Subcutaneous Intravenous Others Diabetes Devices and Therapeutics Market Share by Type of Diabetes Type 1 Diabetes Type 2 Diabetes Diabetes Devices and Therapeutics Market Share by Distribution Channels Online Pharmacies Hospital Pharmacies Retail Pharmacies Diabetes Devices and Therapeutics Market Share by End User Hospitals Diabetes Clinics Homecare Reasons to buy Comprehensive understanding of market structure and dynamics: Gain a detailed view of the diabetes devices and therapeutics market, including category-level segmentation (Diagnosis & Monitoring Devices and Therapeutics) and sub-segmentation by product type, route of administration, type of diabetes, distribution channel, and end user. Identify high-growth segments and strategic investment areas: Use segment-wise market sizing and forecasting to identify opportunities in areas such as continuous glucose monitoring, insulin delivery technologies, oral anti-diabetic drugs, and biosimilars. Tailor your market entry or expansion strategies accordingly. Benchmark performance across distribution and care settings: Access share analysis across online, hospital, and retail pharmacies, and evaluate usage patterns across hospitals, diabetes clinics, and homecare to support channel-specific planning and resource allocation. Key Attributes: Report Attribute Details No. of Pages 840 Forecast Period 2025 - 2029 Estimated Market Value (USD) in 2025 $26.63 Billion Forecasted Market Value (USD) by 2029 $35.43 Billion Compound Annual Growth Rate 7.4% Regions Covered Asia Pacific For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Asia-Pacific Diabetes Devices and Therapeutics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 hours ago
- Yahoo
SELLAS Meets All Primary Endpoints in Phase 2 Trial of SLS009 in r/r AML and Receives FDA Guidance to Advance into First-Line Therapy Study
The Trial Exceeded Target Overall Response Rate (ORR) of 20%, with 44% Response Rate Among Patients with Acute Myeloid Leukemia-Myelodysplasia-Related Changes (AML MR) Treated at Optimal Dose of 30 mg Twice a Week (BIW) and 50% in AML MR with Myelomonocytic/Myelomonoblastic (M4/M5) Subtype Median Overall Survival (mOS) of 8.9 Months in Patients with AML MR and 8.8 mOS in Relapsed or Refractory to Venetoclax-Based Regimens at 30 mg BIW Dose Level Surpasses the Historical Benchmark of 2.4 Months FDA Recommends Advancement towards a Trial Including Newly Diagnosed First-Line AML Patient Cohorts That May Support a New Drug Application; Trial Preparation Underway with Enrollment Expected to Begin by Q1 2026 NEW YORK, July 15, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ('SELLAS' or the 'Company'), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that is has met all primary endpoints in its Phase 2 trial of SLS009 (tambiciclib), a highly selective CDK9 inhibitor, in relapsed/refractory acute myeloid leukemia (r/r AML). The Phase 2 clinical trial of SLS009 is an open-label, single-arm, multi-center study designed to evaluate the safety, tolerability, and efficacy of SLS009 in combination with venetoclax and azacitidine at two dose levels, 45 mg and 60 mg. In the 60 mg dose cohort, patients were treated with either a 60 mg dose once per week or a 30 mg dose two times per week. The trial was expanded to include ASXL1-mutated AML patients as well as patients with myelodysplasia-related cytogenetic abnormalities other than ASXL1 mutations. The target response rate for this Phase 2 trial, at the optimal dose level, was at least 20% and a target median survival of at least 3 months. The primary endpoint for the trial was overall response rate (ORR), and key secondary endpoints included overall survival (OS), safety, and tolerability. The trial met all endpoints, demonstrating strong efficacy and favorable safety and tolerability with robust anti-tumor activity. Based on these data, the Company plans to advance SLS009 into a randomized trial that will expand into the newly diagnosed AML populations where earlier intervention may enhance therapeutic outcomes, as well as patients refractory to venetoclax and azacitidine, with the study to support a potential New Drug Application (NDA) with the FDA. 'We are excited to report that our Phase 2 trial met all key endpoints, with clinical responses and survival outcomes that exceed targeted expectations and historical benchmarks,' said Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS. 'AML remains an area of urgent unmet medical need, particularly for patients with relapsed or refractory disease, where standard treatments are often ineffective and poorly tolerated. What sets SLS009 apart is its consistent efficacy across a broad range of molecular subtypes. The remarkable response rates of 44% among AML MR patients, 50% among ASXL1-mutated AML MR, and 50% among M4/M5 patients at the optimal 30 mg BIW dose far exceed the targeted 20% benchmark. We saw a clear survival benefit with median OS reaching 8.8 months in patients refractory to venetoclax-based regimens in the cohort of patients with median 1 prior line of therapy, surpassing the historical median of 2.4 months and 4.1 months in cohorts with median 2 lines of prior therapy, versus 1.8 months reported in similar patient population. The treatment was also well-tolerated, with no dose-limiting toxicities across any treatment arm, validating both the biological selectivity and safety profile of our approach. We believe these data strongly support the potential of SLS009 to meaningfully extend life in patients with otherwise limited options, and we look forward to sharing these findings in more detail in the future. With the expected Phase 3 REGAL study final analysis by year-end, our galinpepimut-S (GPS) immunotherapy and SLS009 are complementary therapies that together enable us to hopefully address AML patients across the treatment spectrum — from early intervention to maintenance.' Key Phase 2 Results: Patients Characteristics: 54 evaluable r/r AML patients who previously failed venetoclax-based therapies were enrolled and treated with SLS009, and venetoclax/azacitidine; patients were enrolled across all five cohorts. Among the 54 treated patients, 47 had AML MR (87%) and 23 had ASXL1 mutations (43%). 47 out of 54 had AML MR (acute myeloid leukemia with myelodysplasia-related changes). Among AML MR patients,17 had myelomonocytic/myelomonoblastic subtype of AML (M4 and M5), representing 31% of all patients. All patients had adverse risk cytogenetics except one patient who had intermediate risk cytogenetics. The median age of all patients was 69. Median number of prior lines of therapy was 2. Efficacy: The results exceeded the pre-specified ORR threshold of 20%, demonstrating robust clinical activity and supporting advancement into late-stage development. The ORR in all evaluable patients was 33% across all cohorts and dose levels and 40% for the 30mg BIW dose level. At the 30 mg BIW dose, among AML MR patients, the ORR was 44%. The highest efficacy was observed among patients with ASXL1 mutations, with an ORR of 50% (9/18) at 30 mg BIW dose levels and M4/M5 patients with 50% (6/12) ORR. The mOS surpassed the historical benchmark of best available therapy of 2.4 months1 for patients who received one prior line of therapy and 1.8 months for those who received more than one prior line of therapy. The mOS for patients treated with 30mg BIW, with a median of 1 prior line of therapy, was 8.8 months, while the mOS in AML MR patients reached 8.9 months vs. 2.4 months with best available therapy. The mOS for cohorts with a median of 2 prior lines of therapies was 4.1 months vs.1.8 months with best available therapy. Safety: The addition of SLS009 to the venetoclax/azacitidine regimen was well tolerated and did not result in increased toxicities compared to ven/aza alone. No dose-limiting toxicities were observed across all dose levels. Front Line Trial Planning Underway Following FDA Guidance Following a productive end of Phase 2 meeting, the FDA recommended that SELLAS proceeds into a trial to include newly diagnosed, first-line AML patients eligible for venetoclax/azacitidine (aza/ven) therapy, where the agency believes clinical benefit might be greatest. The randomized 80-patient trial is currently in preparation and is expected to begin enrollment by Q1 2026. The trial will include two groups: Predictive biomarker cohort: Newly diagnosed patients unlikely to benefit from standard aza/ven therapy based on molecular profiling Early resistance cohort: Patients who initiate treatment with aza/ven but demonstrate confirmed lack of any response after two treatment cycles This precision approach allows SELLAS to target subpopulations with high unmet need and greatest potential for benefit. 'These SLS009 results represent an important advancement for patients with r/r AML, where treatment options remain limited and outcomes are often poor,' said Dr. Yair Levy, Director of Hematologic Malignancies Research at Texas Oncology Baylor University Medical Center. 'The response rates and survival outcomes are particularly compelling, especially given the consistency of responses across high-risk molecular subtypes and the favorable safety profile. What's especially encouraging is the opportunity to now explore this therapy in the first-line setting, where outcomes are often dictated by how patients respond to initial treatment. The FDA's recognition of this unmet need and its support for a trial in newly diagnosed patients reflects SLS009's potential to address a critical gap in AML care.' 'Following constructive FDA guidance, we are preparing the trial focused on newly diagnosed AML patients as well as those early refractory to venetoclax and azacitidine,' said Dragan Cicic, MD, Chief Development Officer of SELLAS. 'The study will include two groups – one comprising patients predicted not to benefit from standard aza/ven, based on cytogenetic risk factors, and a second comprising patients who begin aza/ven treatment but demonstrate confirmed resistance after two cycles. We believe earlier intervention with SLS009 may offer greater clinical benefit before patients' bone marrow reserve is depleted by disease or prior therapies, and before the disease evolves into more resistant and aggressive forms. Data from other recent clinical trials suggests meaningful differences in response rates between newly diagnosed and relapsed/refractory patients, reinforcing the importance of this strategic approach. In addition, our ongoing collaboration with one of the nation's most prestigious cancer centers continues to generate insights in genomics, proteomics, and transcriptomics, which will refine patient selection and our precision medicine strategy and help us unlock the full potential of SLS009 as we prepare to enter pivotal development.' Zainaldin et al, Leukemia and Lymphoma, 2022 About SELLAS Life Sciences Group, Inc. SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. SELLAS' lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has the potential as a monotherapy and combination with other therapies to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is also developing SLS009 (tambiciclib) - potentially the first and best-in-class differentiated small molecule CDK9 inhibitor with reduced toxicity and increased potency compared to other CDK9 inhibitors. Data suggests that SLS009 demonstrated a high response rate in AML patients with unfavorable prognostic factors including ASXL1 mutation, commonly associated with poor prognosis in various myeloid diseases. For more information on SELLAS, please visit Forward-Looking Statements This press release contains forward-looking statements. All statements other than statements of historical facts are 'forward-looking statements,' including those relating to future events. In some cases, forward-looking statements can be identified by terminology such as 'plan,' 'expect,' 'anticipate,' 'may,' 'might,' 'will,' 'should,' 'project,' 'believe,' 'estimate,' 'predict,' 'potential,' 'intend,' or 'continue' and other words or terms of similar meaning. These statements include, without limitation, statements related to the GPS clinical development program, including the REGAL study and the timing of future milestones related thereto. These forward-looking statements are based on current plans, objectives, estimates, expectations, and intentions, and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties with oncology product development and clinical success thereof, the uncertainty of regulatory approval, and other risks and uncertainties affecting SELLAS and its development programs as set forth under the caption 'Risk Factors' in SELLAS' Annual Report on Form 10-K filed on March 20, 2025 and in its other SEC filings. Other risks and uncertainties of which SELLAS is not currently aware may also affect SELLAS' forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof. SELLAS undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations, or other circumstances that exist after the date as of which the forward-looking statements were made. Investor Contact John Fraunces Managing Director LifeSci Advisors, LLC jfraunces@
